Skip to main content

Table 4 Correlation between EGFR–TP53 mutant combinations and the clinical, pathological and imaging features and risk grouping of patients

From: Correlation analysis of clinical, pathological, imaging and genetic features of ground-glass nodule featured lung adenocarcinomas between high-risk and non-high-risk individuals

 

EGFR + /TP53 + 

N = 55

EGFR + /TP53-

N = 237

EGFR-/TP53-

N = 170

EGFR-/TP53 + 

N = 11

P value

Age

    

 < 0.001*

 

57.42 ± 9.473 a

54.34 ± 11.545 a

51.06 ± 11.286 b

58.36 ± 9.244 a

 

Gender

    

 < 0.001*

 Male

27 (49.09)a

70 (29.54)b

47 (27.65)b

9 (81.82)a

 

 Female

28 (50.91)a

167 (70.46)b

123 (72.35)b

2 (18.18)a

 

Smoking history

    

 < 0.001*

 Yes

9 (16.36)a

31 (13.08)a

21 (12.35)a

9 (81.82)b

 

 No

46 (83.64)a

206 (86.92)a

149 (87.65)a

2 (18.18)b

 

Family history of lung cancer

    

0.571

 Yes

5 (9.09)a

22 (9.28)a

20 (11.76)a

0 (0.00)a

 

 No

50 (90.91)a

215 (90.72)a

150 (88.23)a

11 (100.00)a

 

Family history of other tumors

    

0.644

 Yes

7 (12.73)a

26 (10.97)a

17 (10.00)a

0 (0.00)a

 

 No

48 (87.27)a

211 (89.03)a

153 (90.00)a

11 (100.00)a

 

Nodule location

    

0.109

 Right superior lobe

22 (40.00)a,b

84 (35.44)b

63 (37.06)b

9 (81.82)a

 

 Right middle lobe

3 (5.45)a

14 (5.91)a

8 (4.71)a

0 (0.00)a

 

 Right inferior lobe

6 (10.91)a

46 (19.41)a

26 (15.29)a

0 (0.00)a

 

 Left superior lobe

13 (23.64)a

64 (27.00)a

56 (32.94)a

2 (18.18)a

 

 Left inferior lobe

11 (20.00)a

29 (12.24)a

17 (10.00)a

0 (0.00)a

 

Imaging sign

     

 Lobulation

16 (29.09)a

50 (21.10)a

27 (15.88)a

2 (18.18)a

0.185

 Vacuole

9 (16.36)a

37 (15.61)a

29 (17.06)a

1 (9.09)a

0.905

 Spiculation

13 (23.64)a

42 (17.72)a

14 (8.24)b

2 (18.18)a,b

0.013*

 Calcification

0 (0.00)a

2 (0.84)a

3 (1.76)a

0 (0.00)a

0.654

 Air bronchogram

1 (1.82)a

7 (2.95)a

4 (2.35)a

0 (0.00)a

0.899

 Pleural indentation

16 (29.09)a

54 (22.78)a

16 (9.41)b

1 (9.09)a,b

0.001*

 Vessel convergence

2 (3.64)a

9 (3.80)a

6 (3.53)a

0 (0.00)a

0.509

Clinical stage

    

0.020*

 IA

40 (72.73)a

211 (89.03)b

155 (91.18)b

10 (90.91)a,b

 

 IB

13 (23.64)a

24 (10.13)b

14 (8.24)b

1 (9.09)a,b

 

 IIB

2 (3.64)a

2 (0.84)a

1 (0.59)a

0 (0.00)a

 

Pathological subtype c (n = 411)

    

 < 0.001*

 AAH + AIS

0 (0.00)a

6 (2.96)a

10 (6.67)a

0 (0.00)a

 

 MIA

7 (14.89)a

63 (31.03)a

84 (56.00)b

2 (18.18)a,b

 

 IAC

40 (85.11)a

134 (66.01)a

56 (37.33)b

9 (81.82)a

 

Risk grouping

    

0.081

 High risk

20 (36.36)a

52 (21.94)a

34 (20.00)a

2 (18.18)a

 

 Non-high risk

35 (63.64)a

185 (78.06)a

136 (80.00)a

9 (81.82)a

 
  1. The same subscript letter indicates the difference between mutant combinations is not statistically significant (P > 0.05), while different subscripts indicate the difference between mutant combinations is statistically significant (P < 0.05). Age is expressed as Mean ± SD and the rest is expressed as frequency (percentage)
  2. *P < 0.05 or P < 0.01 after Bonferroni correction is considered statistically different
  3. c411/473 cases were classified pathologically according to the existing pathological subtypes
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us